HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER

Clinical trials for HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER explained in plain language.

Never miss a new study

Get alerted when new HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER trials appear

Sign up with your email to follow new studies for HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Terminated trial tests cancer drug for rare, aggressive tumors

Disease control Terminated

This study tested whether an existing cancer drug called TAS-102 could help patients with a rare, aggressive form of neuroendocrine cancer that starts outside the lungs. The trial enrolled 14 patients who had already tried platinum-based chemotherapy, aiming to see if TAS-102 cou…

Matched conditions: HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER

Phase: PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control

Last updated Apr 02, 2026 07:26 UTC

HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER

Get alerted when new HIGH-GRADE EXTRA PULMONARY NEUROENDOCRINE CANCER trials appear

Terminated trial tests cancer drug for rare, aggressive tumors